scholarly journals Reducing PTSD symptoms through a gender norms and economic empowerment intervention to reduce intimate partner violence: a randomized controlled pilot study in Côte D'Ivoire

2017 ◽  
Vol 4 ◽  
Author(s):  
J. Annan ◽  
K. Falb ◽  
D. Kpebo ◽  
M. Hossain ◽  
J. Gupta

Background.Women living in war-affected contexts face high levels of gender-based violence, including intimate partner violence (Stark & Ager, 2011). Despite well-documented negative consequences, including posttraumatic stress disorder (PTSD) (Garcia-Moreno et al. 2006; Steel et al. 2009), evidence remains thin regarding intervention effectiveness to mitigate consequences in these settings.Methods.This study used a two-armed parallel pilot randomized controlled trial to compare the impact of a group savings only (control) to gender dialogue groups added to group savings (treatment) on women's symptoms of PTSD in northwestern Côte d'Ivoire. Eligible Ivorian women (18+ years, no prior experience with group savings) were invited to participate and 1198 were randomized into treatment groups.Results.In the ITT analyses, women in the treatment arm had significantly fewer PTSD symptoms relative to the control arm (β: −0.12; 95% CI: −0.20 to −0.03; p = 0.005). Partnered women in the treatment arm who had not experienced intimate partner violence (IPV) at baseline had significantly fewer PTSD symptoms than the control arm (β = −0.12; 95% CI: −0.21 to −0.03; p = 0.008), while those who had experienced IPV did not show significant differences between treatment and control arms (β = −0.09; 95% CI: −0.29 to 0.11; p = 0.40).Conclusions.Adding a couples gender discussion group to a women's savings group significantly reduced women's PTSD symptoms overall. Different patterns emerge for women who experienced IPV at baseline v. those who did not. More research is needed on interventions to improve mental health symptoms for women with and without IPV experiences in settings affected by conflict.

PLoS ONE ◽  
2016 ◽  
Vol 11 (6) ◽  
pp. e0157348 ◽  
Author(s):  
Sara J. Shuman ◽  
Kathryn L. Falb ◽  
Lauren F. Cardoso ◽  
Heather Cole ◽  
Denise Kpebo ◽  
...  

PLoS ONE ◽  
2014 ◽  
Vol 9 (5) ◽  
pp. e96300 ◽  
Author(s):  
Jhumka Gupta ◽  
Kathryn L. Falb ◽  
Hannah Carliner ◽  
Mazeda Hossain ◽  
Denise Kpebo ◽  
...  

2021 ◽  
Author(s):  
Matthew Cock

Abstract Writing about Zophopetes cerymica (which they considered more common) and P. laufella combined, Mariau and Morin (1974) state that attacks can be on palms of all ages, including young palms recently planted out. At this age, defoliation of the plants delays their subsequent development. Outbreaks on older trees are rarer, and the damage often less important; these attacks are generally localized at the edge of plantations. Mariau et al. (1981) add that the highest fronds are the most often damaged. Herder et al. (1994) refer to regular outbreaks of P. laufella on oil palm in southern Côte d'Ivoire. There are no more substantive reports on the impact of the feeding damage by these hesperiids.


Author(s):  
Chandni Patel ◽  
Jean T Coulibaly ◽  
Daniela Hofmann ◽  
Yves N’Gbesso ◽  
Jan Hattendorf ◽  
...  

Abstract Background Infections with hookworms affect about half a billion people worldwide. Recommended therapy includes 400 mg of albendazole, which is moderately efficacious. Higher doses have been rarely assessed. Methods A randomized, controlled dose-finding trial was conducted in Côte d’Ivoire with the aim of recruiting 120 preschool-aged children (PSAC), 200 school-aged children (SAC), and 200 adults. Eligible PSAC were randomized 1:1:1 to 200 mg, 400 mg, or 600 mg of albendazole; the other age groups were randomized 1:1:1:1:1 to placebo or 200 mg, 400 mg, 600 mg, or 800 mg. The primary outcome was cure rates (CRs) assessed 14–21 days post-treatment by quadruplicate Kato-Katz thick smears. Hyperbolic Emax models were used to determine dose-response. Results 38 PSAC, 133 SAC, and 196 adults were enrolled. In adults, predicted CRs increased with ascending doses of albendazole, with a CR of 74.9% (95% confidence interval [CI], 55.6%–87.7%) in the 800-mg arm. Observed CRs increased with ascending doses of albendazole reaching a maximum of 94.1% (95% CI, 80.3%–99.3%). In SAC, the predicted dose-response curve increased marginally, with CRs ranging from 64.0% in the 200-mg arm to 76.0% in the 800-mg arm. Sample size in PSAC was considered too small to derive meaningful conclusions. 10.7% and 5.1% of participants reported any adverse event at 3 hours and 24 hours post-treatment, respectively. Conclusions A single 800-mg albendazole dose provides higher efficacy against hookworm and is well tolerated in adults and should be considered for community-based strategies targeting adults. For PSAC and SAC, current recommendations suffice. Clinical Trials Registration NCT03527745.


2019 ◽  
Vol 665 ◽  
pp. 1158-1167 ◽  
Author(s):  
Robert P. Mason ◽  
Zofia Baumann ◽  
Gunnar Hansen ◽  
Koffi Marcellin Yao ◽  
Mariame Coulibaly ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document